Courts will be busy with biosimilar litigation for the foreseeable future, attorneys predicted at a panel on the second day of the ACI 10th Summit on Biosimilars.
There have been changes to the biosimilar “ecosystem” that will keep federal dockets busy with litigation for the foreseeable future, according to a panel discussing trends in antitrust issues at the ACI 10th Summit on Biosimilars.
An increased number of biosimilar applications have been filed that target extremely successful reference products, noted Vernon M. Winters, JD, of Sidley Austin LLP. It is speculated by industry observers that there are 10 applications pending at the FDA, he said.
As of the end of May, there have been 32 cases filed under the Biologics Price Competition and Innovation Act (BPCIA), although many concerned BPCIA disclosure and patent dance obligations, or what he called “procedural skirmishes,” he said. While outright “pay-for-delay” settlements are on the decline, he said, citing a report from the Federal Trade Commission, outright patent litigation is clearly part of the biosimilar environment.
Winters also discussed the 2016 Supreme Court divided ruling in FTC v Actavis that a brand-name drug maker’s payment to a generic competitor to settle patent litigation can violate antitrust laws.
Under that ruling, a dozen or so lawsuits have been filed against AbbVie over its blockbuster brand-name adalimumab, Humira, for alleged use of a patent thicket to maintain a monopoly. The lawsuits include those from various unions, who allege that they have paid artificially high prices.
In addition, Nicholas Groombridge, JD, of Paul, Weiss, Wharton & Garrison LLP, discussed the issues surrounding the Pfizer Inc v Johnson & Johnson antitrust suit over Johnson & Johnson’s originator infliximab (Remicade). The suit, filed in September 2017, alleges that Johnson & Johnson engaged in exclusionary contracts, bundled rebates, and multiproduct bundling practices related to its originator infliximab that have effectively denied patients access to biosimilar therapies (including Pfizer’s Inflectra) and have undermined price competition in the biologics marketplace.
Discovery in the case is ongoing, he said, with more than 170 nonparty subpoenas and ongoing disputes over the scope and timing of discovery.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Panelists Deliberate Strategies to Enhance Biosimilar Integration in Managed Care Spaces
November 13th 2023At the recent Academy of Managed Care Pharmacy Nexus meeting, panelists discussed the impact of introducing biosimilars in new medical fields, emphasizing the need for more education and collaboration to ensure their smooth integration into health care systems.
BioRationality: FDA Launches a New Opportunity to Remove Redundant Trials of Biosimilars
November 6th 2023The FDA introduced a plan to improve clinical trials, including a provision to possibly eliminate clinical efficacy testing for biologic products, which evidence has suggested may not be necessary, according to Sarfaraz K. Niazi, PhD.